Edwards Lifesciences (EW) EBT (2009 - 2026)

Edwards Lifesciences has reported EBT for 18 years, with the latest figure at $519.8 million in Q2 2026.

• On a quarterly basis, EBT rose 29.89% year-over-year to $519.8 million in Q2 2026; TTM through Jun 2026 was $1.4 billion, a 12.87% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, down 17.78% from the prior year.
• EBT was $519.8 million for Q2 2026 at Edwards Lifesciences, up from $459.0 million in the prior quarter.
• The five-year high for EBT was $519.8 million in Q2 2026, with the low at $90.4 million in Q4 2025.
• Average EBT over 5 years is $374.9 million, with a median of $394.3 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: EBT jumped 73.7% in 2023, then slumped 76.83% in 2025.
• Over 5 years, EBT stood at $211.4 million in 2022, then jumped by 73.7% to $367.2 million in 2023, then rose by 6.24% to $390.1 million in 2024, then plunged by 76.83% to $90.4 million in 2025, then surged by 475.0% to $519.8 million in 2026.
• The last three EBT figures came in at $519.8 million (Q2 2026), $459.0 million (Q1 2026), and $90.4 million (Q4 2025), per Business Quant data.